Zeng Y - Search Results

1

Genomic profiles and their associations with TMB, PD-L1 expression, and immune cell infiltration landscapes in synchronous multiple primary lung cancers.

Hu C, Zhao L, Liu W, Fan S, Liu J, Liu Y, Liu X, Shu L, Liu X, Liu P, Deng C, Qiu Z, Chen C, Jiang Y, Liang Q, Yang L, Shao Y, He Q, Yu D, Zeng Y, Li Y, Pan Y, Zhang S, Shi S, Peng Y, Wu F. Hu C, et al. Among authors: zeng y. J Immunother Cancer. 2021 Dec;9(12):e003773. doi: 10.1136/jitc-2021-003773. J Immunother Cancer. 2021. PMID: 34887263 Free PMC article.

2

Clinical treatment options for early-stage and advanced conjunctival melanoma.

Zeng Y, Hu C, Shu L, Pan Y, Zhao L, Pu X, Wu F. Zeng Y, et al. Surv Ophthalmol. 2021 May-Jun;66(3):461-470. doi: 10.1016/j.survophthal.2020.09.004. Epub 2020 Sep 25. Surv Ophthalmol. 2021. PMID: 32980421 Review.

3

DNA methyltransferase inhibitors combination therapy for the treatment of solid tumor: mechanism and clinical application.

Hu C, Liu X, Zeng Y, Liu J, Wu F. Hu C, et al. Among authors: zeng y. Clin Epigenetics. 2021 Aug 27;13(1):166. doi: 10.1186/s13148-021-01154-x. Clin Epigenetics. 2021. PMID: 34452630 Free PMC article. Review.

4

Resistance mechanisms to osimertinib and emerging therapeutic strategies in nonsmall cell lung cancer.

Zeng Y, Yu D, Tian W, Wu F. Zeng Y, et al. Curr Opin Oncol. 2022 Jan 1;34(1):54-65. doi: 10.1097/CCO.0000000000000805. Curr Opin Oncol. 2022. PMID: 34669648 Review.

5

Chronic Stress: Impacts on Tumor Microenvironment and Implications for Anti-Cancer Treatments.

Tian W, Liu Y, Cao C, Zeng Y, Pan Y, Liu X, Peng Y, Wu F. Tian W, et al. Among authors: zeng y. Front Cell Dev Biol. 2021 Nov 19;9:777018. doi: 10.3389/fcell.2021.777018. eCollection 2021. Front Cell Dev Biol. 2021. PMID: 34869378 Free PMC article. Review.

6

Dramatic response to brigatinib in a lung adenocarcinoma patient harboring EML4-ALK fusion and a G1202R de novo gene mutation.

Pan Y, Zeng Y, Peng Y, Liu X, Li Y, Wu F. Pan Y, et al. Among authors: zeng y. Eur J Cancer. 2022 Apr;165:154-156. doi: 10.1016/j.ejca.2022.02.001. Epub 2022 Feb 27. Eur J Cancer. 2022. PMID: 35235872 No abstract available.

7

The key to immunotherapy: how to choose better therapeutic biomarkers for patients with non-small cell lung cancer.

Pan Y, Fu Y, Zeng Y, Liu X, Peng Y, Hu C, Deng C, Qiu Z, Zou J, Liu Y, Wu F. Pan Y, et al. Among authors: zeng y. Biomark Res. 2022 Mar 7;10(1):9. doi: 10.1186/s40364-022-00355-7. Biomark Res. 2022. PMID: 35255999 Free PMC article. Review.

8

Corrigendum: Chronic Stress: Impacts on Tumor Microenvironment and Implications for Anti-Cancer Treatments.

Tian W, Liu Y, Cao C, Zeng Y, Pan Y, Liu X, Peng Y, Wu F. Tian W, et al. Among authors: zeng y. Front Cell Dev Biol. 2022 Mar 4;10:865043. doi: 10.3389/fcell.2022.865043. eCollection 2022. Front Cell Dev Biol. 2022. PMID: 35317388 Free PMC article.

9

[Research Progress of Immunotherapy for Non-small Cell Lung Cancer  with Drive Gene Mutation].

Deng R, Zeng Y, Pan Y, Hu C, Wu F. Deng R, et al. Among authors: zeng y. Zhongguo Fei Ai Za Zhi. 2022 Mar 20;25(3):201-206. doi: 10.3779/j.issn.1009-3419.2022.102.06. Zhongguo Fei Ai Za Zhi. 2022. PMID: 35340163 Free PMC article. Review. Chinese.

10

Acquired Concurrent EGFR T790M and Driver Gene Resistance From EGFR-TKIs Hampered Osimertinib Efficacy in Advanced Lung Adenocarcinoma: Case Reports.

Zeng Y, Feng Y, Fu G, Jiang J, Liu X, Pan Y, Hu C, Liu X, Wu F. Zeng Y, et al. Front Pharmacol. 2022 Apr 6;13:838247. doi: 10.3389/fphar.2022.838247. eCollection 2022. Front Pharmacol. 2022. PMID: 35462930 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

15,354 results

Search Page

Filters